Astrostem-V / Nature Cell - LARVOL DELTA

Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia (clinicaltrials.gov) - P1/2 | N=10 | Recruiting | Sponsor: Nature Cell Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Pneumonia

Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: Nature Cell Co. Ltd. | Trial completion date: Apr 2023 ➔ Dec 2023 | Trial primary completion date: Oct 2022 ➔ Nov 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia

Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia (clinicaltrials.gov) - P1/2; N=10; Not yet recruiting; Sponsor: Nature Cell Co. Ltd.; Trial completion date: Apr 2022 ➔ Apr 2023; Initiation date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Oct 2021 ➔ Oct 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • PCR

Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia (clinicaltrials.gov) - P1/2; N=10; Not yet recruiting; Sponsor: Nature Cell Co. Ltd.

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • PCR

Phase update (clinicaltrials.gov) - Preclinical➔P2, Novel Coronavirus Disease

Phase shift • Novel Coronavirus Disease

Nature Cell, Corona 19-related stem cell therapy clinical application to the US FDA (Seoul Wire) - "Nature Cell...is planning to conduct a clinical trial in the United States for the stem cell treatment agent Astrostem-V in patients with pneumonia caused by Corona19. According to the announcement, Nature Cell announced that it has applied for a clinical trial plan for Phase A in the US Astrostem-V....When the patient is enrolled in the clinical trial after passing the screening, the clinical trial is conducted by receiving the stem cells of the immediate kin family within 2 villages, undergoing the culturing process, and then receiving the clinical trial drug to the patient. After dosing, safety and efficacy are assessed through follow-up for 8 weeks at 1-week intervals."

New trial • Regulatory • Infectious Disease • Novel Coronavirus Disease